Selective inhibition of COX-2 in humans is associated with less gastrointestinal injury: A comparison of nimesulide and naproxen

Gut

Volumn 48, Issue 3, 2001, Pages 339-346

  Shah, A A ^b   Fitzgerald, D J ^a,b   Bjarnason, I ^d   Thjodleifsson, B ^c   Murray, F E ^b   Kay, E ^b   Barry, M ^b   Sigthorsson, G ^d   Gudjonsson, H ^c   Oddsson, E ^c   Price, A B ^d  

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^b BEAUMONT HOSPITAL   (Ireland)

^c LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

^d KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Cyclooxygenase; Non steroidal anti inflammatory drug enteropathy; Platelet aggregation; Prostaglandins

Indexed keywords

CALPROTECTIN; NAPROXEN; NIMESULIDE; PROSTACYCLIN; PROSTAGLANDIN E2; THROMBOXANE B2;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIGESTIVE SYSTEM INJURY; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; DRUG SAFETY; DRUG SPECIFICITY; HUMAN; HUMAN EXPERIMENT; NORMAL HUMAN; PRIORITY JOURNAL; PROSTAGLANDIN RELEASE; SCORING SYSTEM; STOMACH BIOPSY; THROMBOCYTE AGGREGATION;

ADOLESCENT; ADULT; AGED; BIOLOGICAL MARKERS; CROSS-OVER STUDIES; CYCLOOXYGENASE INHIBITORS; DOUBLE-BLIND METHOD; FEMALE; GASTRIC MUCOSA; GASTROINTESTINAL DISEASES; HUMANS; INTESTINAL MUCOSA; MALE; MIDDLE AGED; NAPROXEN; PERMEABILITY; PLATELET AGGREGATION; PROSTAGLANDINS E; SULFONAMIDES; THROMBOXANE B2;

EID: 0035062842     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.48.3.339     Document Type: Article

References (57)

1. FDA arthritis advisory committee meeting: Postmarketing surveillance of non-steroidal antiinflammatory drugs
2. Epidemiologic evidence of the association between peptic ulceration and anti-inflammatory drug use
3. Nonsteroidal anti-inflammatory drugs and serious gastrointestinal adverse reactions-I
4. Nonsteroidal anti-inflammatory drugs and serious gastrointestinal adverse reactions-II
5. Side effects of non-steroidal antiinflammatory drugs on the small and large intestine
6. Misoprostol reduces serious complications in patients with rheumatoid arthritis receiving NSAID
7. The prevalence of duodenal lesions in patients with rheumatic disease on chronic aspirin therapy
8. Risk for serious gastrointestinal complications related to use of NSAID's. A meta-analysis
9. Non-steroidal anti-inflammatory drugs and life threatening complications of peptic ulceration
10. Blood and protein loss via small intestinal inflammation induced by non steroidal anti-inflammatory drugs
11. Multiple strictures of small intestine after long term NSAID drug therapy
12. Isolation and characterization of the complementary DNA for sheep seminal vesicle prostaglandin endoperoxide synthase cyclooxygenase
13. Serum and glucocorticoid regulation of gene transcription and expression of the prostaglandin H synthase-1 and prostaglandin H synthase-2 isozymes
14. Molecular cloning of human prostaglandin endoperoxide synthase type II and demonstration of expression in response to cytokines
15. cDNA cloning and functional activity of a glucocorticoid-regulated inflammatory cyclooxygenase
16. Inducible isoforms of cyclooxygenase and nitric oxide synthase in inflammation
17. Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain
18. Characterization of prostaglandin G/H synthase 1 and 2 in rat, dog, monkey, and human gastrointestinal tracts
19. Increased expression and cellular localization of inducible nitric oxide synthase and cyclooxygenase 2 in Helicobacter pylori gastritis
20. Selective inhibition of inducible cyclooxygenase 2 in vivo is anti-inflammatory and nonulcerogenic
21. Clinical pharmacology of platelet cyclooxygenase inhibition
22. Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid induced inflammation and indomethacin-induced gastric ulceration
23. Differential inhibition of human prostaglandin endoperoxide H synthases-1 and -2 by nonsteroidal anti-inflammatory drugs
24. Pharmacology of a selective cyclooxygenase-2 inhibitor, L-745,337: A novel nonsteroidal anti-inflammatory agent with an ulcerogenic sparing effect in rat and nonhuman primate stomach
25. 1,2-Diarylpyrroles as potent and selective inhibitors of cyclooxygenase-2
26. Selective inhibition of COX-2 by nimesulide in man
27. Selective inhibition by nimesulide, a novel non-steroidal anti-inflammatory drug, of prostaglandin endoperoxide synthase-2 activity in vitro
28. Endoscopic studies of gastric and duodenal injury after the use of ibuprofen, aspirin and other NSAIDs
29. Visual analogue scale for endoscopic evaluation of NSAID-induced mucosal damage in the stomach and the duodenum
30. Classification and grading of gastritis
31. Intestinal permeability: An overview
32. Intestinal permeability in patients with Crohn's disease and their first degree relatives
33. Intestinal permeability and function in patients infected with human immuno-deficiency virus
34. Quantitative estimation of clinically important monosaccharides in plasma by rapid thin layer chromatography
35. Transmucosal passage of inert molecules in health and disease
36. Distribution of a new myelomonocytic antigen (L-1) in human peripheral blood leucocytes
37. Assessment of neutrophil dominating calprotectin in faeces. A methodological study
38. Effects of the novel anti-inflammatory compounds, N-[2-(cyclohexyloxy)-4nitrophenyl] methanesulphonamide (NS398) and 5-methanesulphonamido-6-(2,4 -difluor thio-phenyl)-1-indanone (L-745,337), on the cyclo-oxygenase of human blood prostaglandin endoperoxide synthases
39. The use of non-parametric methods in the statistical analysis of the two-period change-over design
40. Prostaglandin E2 and prostaglandin F2 alpha biosynthesis in human gastric mucosa: Effect of chronic alcohol misuse
41. Association of upper gastro-intestinal toxicity of NSAIDs with continued exposure: Cohort study
42. A clinicopathological feature of NSAID induced small intestinal strictures
43. A randomized, double-blind, cross-over, competitive endoscopy study on the gastrointestinal tolerability of a highly specific COX-2 inhibitor flosulide and naproxen
44. An endoscopic comparision of the effect of etodolac, indomethacin, ibuprofen, naproxen and placebo on the gastro-intestinal mucosa
45. The prevention and healing of acute NSAID-associated gastroduodenal mucosal damage by misoprostol
46. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: A randomized controlled trial
47. Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: A randomized, double-blind, placebocontrolled trial
48. Peptic ulcer bleeding in the elderly: Relative roles of Helicobacter pylori and NSAIDs
49. A comparison of indomethacin and nimesulide, a selective COX-2 inhibitor, on key patho-physiological steps in the pathogenesis of NSAID enteropathy in the rat
50. Cr ethylenediaminetetraacetic acid absorption test. Effect of naproxen, a non-steroidal anti-inflammatory drug
51. Intestinal permeability and inflammation in patients on NSAIDs
52. NSAID-induced intestinal inflammation in humans
53. Faecal calprotectin shedding after short term treatment with NSAIDs
54. Estimated rate of prostacyclin secretion into the circulation of normal man
55. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: The human pharmacology of a selective inhibitor of COX-2
56. Inhibition of platelet function by low dose acetylsalicylic acid in patients with cerebrovascular disease
57. Cyclooxygenase 1 contributes to inflammatory responses in rats and mice: Implications for gastrointestinal toxicity